Given that silencing TRAF3IP2 lowers the expression of proinflammatory cytokines (IL-1β, IL-6, IL-8) and angiogenic mediators [49], its downregulation in neuronal EVs may indicate a compensatory mechanism aimed at decreasing neuroinflammation or limiting inflammatory signaling in PD pathology. Here, IL6 is linked to Parkinson disease.